

Full Length Research Paper

# Frequency of extended spectrum beta-lactamase producing *Klebsiella pneumoniae* isolated from blood in Vojvodina, Serbia during 2009 to 2010

Medić Deana\*, Gusman Vera, Jelesić Zora and Mihajlović-Ukropina Mira

Institute of Public Health of Vojvodina, Center for Microbiology, Novi Sad, Serbia.

Accepted 16 November, 2011

The prevalence of extended-spectrum beta-lactamases (ESBL) varies between countries. The aim of this study was to determine the prevalence of ESBL producing *Klebsiella pneumoniae* originating from blood in the Vojvodina Province, Serbia. The study was conducted at Institute of Public Health of Vojvodina in Novi Sad, Serbia, in a two year period from January 2009 to December 2010. A total of 11894 blood samples from patients admitted to the Center were obtained for culture. Seventy-seven isolates of *K. pneumoniae* were reported. Antibiotic susceptibility testing and detection of ESBL production were carried out according to Clinical and Laboratory Standards Institute (CLSI) criteria. The ESBL phenotype was detected in 16 (53.3%) and 32 (68.1%) isolates in 2009 and 2010, respectively. Resistance to piperacillin/tazobactam increased from 43.7% in 2009 to 75% in 2010 while for amoxicillin/clavulanic acid decreased from 75 to 71.9% in the same period. Amikacin was more effective than gentamicin. More than 80% of isolates were resistant to cotrimoxazole and ciprofloxacin. All ESBL-producing isolates tested were sensitive to carbapenems. This study shows a very high prevalence of ESBL-producing *K. pneumoniae* among hospitalized patients with bloodstream infections and suggests that amikacin should be considered as synergistic antibiotic for the treatment of these infections together with other antimicrobial drugs.

**Key words:** *Klebsiella pneumoniae*, blood culture, antimicrobial resistance, extended spectrum beta lactamase.

## INTRODUCTION

*Klebsiella* species, member of Enterobacteriaceae family is widely distributed in soil, water and the intestinal tract of humans and animals. Among *Klebsiella* species, *Klebsiella pneumoniae* (*K. pneumoniae*) is an important opportunistic nosocomial pathogen causing several

diseases including pneumonia, wound and urinary tract infections, bacteriemia and meningitis. Immunocompromised patients, patients with severe underlying disease as well as those submitted to invasive diagnostic procedures and who stayed in the intensive care unit are the most susceptible to these infections. Risk factors for colonization and infection are recent surgery, central venous catheters, tracheotomy, parenteral nutrition, and uncontrolled use of broad spectrum antibiotics (third generation cephalosporins, fluoroquinolones, carbapenems). Reservoirs of infection are intestinal and respiratory tract of hospitalized patients and hospital staff, and the way of transmissions are the hands of the staff or contaminated medical equipment and fluids (Shayanfar et al., 2004; Kang et al., 2004; Abbott, 2003). Due to irrational use of antibiotics, *K. pneumoniae* isolated from

\*Corresponding author. E-mail: [medicgz@eunet.rs](mailto:medicgz@eunet.rs). Tel: +381641150755. Fax: +381216613989.

**Abbreviations:** ESBL, Extended spectrum beta-lactamase; MDR, multidrug resistant; KPC, *Klebsiella pneumoniae* carbapenemase; NDM-1, New Delhi metallo-beta lactamase -1; CLSI, clinical laboratory standards institute, ATCC, American type culture collection; SPSS, statistical package for the social sciences, ICU - intensive care unit.

blood culture is mostly multidrug resistant (MDR) to three or more antibiotic classes often producing beta-lactamases (Kang et al., 2004). The problem of a great concern is the emergence of *K. pneumoniae* strains producing extended spectrum beta-lactamases (ESBLs). ESBLs are plasmid mediated beta-lactamases capable of efficiently hydrolyzing all beta-lactam antibiotics including 3rd generation cephalosporins and monobactams, but not carbapenems (Mehrgan and Rahabar, 2008).

The first occurrence of ESBL producing organism was observed in France and Germany in 1983, and thereafter around the world (Paterson and Bonomo, 2005; Gagliotti et al., 2008). Until now more than 70 ESBLs have been described and most of them are members of TEM-1, TEM-2 and SHV-1 family of enzymes (Shayanfar et al., 2010; Behrooz et al., 2010). During the past decade, rapid and massive spread of CTX-M-type ESBLs has been described. Now these enzymes are the most prevalent ESBLs in Enterobacteriaceae in Europe and in other areas of the World (Dallenne et al., 2010). The presence of ESBL-producing isolates is an indicator of the selective pressure of 3rd generation of cephalosporins which are extensively used in hospitals. Blood stream infections caused by ESBL producing bacteria were associated with longer, more costly hospital stays and high mortality rates (Ambretti et al., 2010).

The plasmid encoding ESBLs frequently also encodes the resistance to other classes of antimicrobials including fluoroquinolones and aminoglycosides leaving a few therapeutic options available for treatment (Abhilash et al., 2010; Eurosurveillance, 2010). Carbapenems that are stable to most of the prevalent beta-lactamases including ESBLs have become the treatment of choice for infection due to the ESBL producing strains. The first strain of *K. pneumoniae* producing plasmid-determined enzymes for inhibition of carbapenems was reported in 1996. They were serine carbapenemase KPC (*K. pneumoniae* carbapenemase). The majority of KPC harboring *K. pneumoniae* has been collected in the northeastern USA, they quickly spread and often appear in Israel and Greece, with outbreaks or isolated cases in hospitals in other European countries (Marschall et al., 2009; Woodford et al., 2004; Giakkoupi et al., 2009; Samuelsen et al., 2009; Grundmann et al., 2011).

Since 2008, Enterobacteriaceae producing New Delhi metallo-beta lactamase -1 (NDM-1) have been imported repeatedly into Europe from the Indian subcontinent particularly into the United Kingdom, but also to Austria, Belgium, France, Germany, The Netherlands, Norway and Sweden. Most of them were resistant to all antibiotics, except polymyxins, tigecycline and occasionally certain aminoglycosides. NDM-1 producers are mainly *K. pneumoniae* (Grundmann et al., 2011). It is necessary to investigate the frequency of ESBL and KPC positive strains in hospitals in order to formulate the policy of empirical therapy in high risk units where infections due to resistant organisms are much higher. The aim of this

study was to determine prevalence of ESBL producing *K. pneumoniae* originating from blood in Vojvodina Province.

## MATERIALS AND METHODS

### Study design and specimen types

The study was conducted at the Center for Microbiology of Institute of Public Health of Vojvodina, Serbia. Samples of blood cultures from adult patients hospitalized on the various wards of Clinical center of Vojvodina Province were collected from January 2009 to December 2010. A total of 77 non-duplicate strains of *K. pneumoniae* were isolated. During the two year study period, 11894 blood samples were processed: 5753 samples in 2009 and 6141 in 2010.

### Microbiological methods

All blood samples were routinely cultured in adult blood culture bottles (BioMérieux, Marcy' Etoile, France) using standard precautions and processed by semi-automated blood culture system (BacT /Alert, BioMérieux, Marcy' Etoile, France). The positive samples were inoculated onto blood agar and MacConkey agar plates (HiMedia, India) that were incubated aerobically 24 h at 37°C. Isolation and identification of the causative organisms were performed by standard microbiological methods.

### Antimicrobial susceptibility testing

Susceptibility to antimicrobial agents was tested by standard disk-diffusion method on Mueller-Hinton agar (HiMedia, India) using antibiotic discs BioRad, USA. The performance and interpretation were based on the recommendations of Clinical Laboratory Standards Institute (CLSI, 2009, 2010). The following antimicrobial agents were tested: ampicillin, cefalotin, ceftriaxone, ceftazidime, amoxicillin/clavulanic acid, piperacillin/tazobactam, meropenem, imipenem, ertapenem, gentamicin, amikacin, cotrimoxazole and ciprofloxacin. *Escherichia coli* American Type Culture Collection (ATCC) 25922 and *Staphylococcus aureus* ATCC 25923 were used for quality controls.

### Detection of extended spectrum beta lactamases (ESBL) production

The initial screening and phenotypic confirmatory test was recommended by CLSI (CLSI, 2009, 2010). In this test a disc of amoxicillin/clavulanic acid was placed in center of the Petri plate already inoculated with the test microorganism while cefotaxime, ceftazidime and ceftriaxone discs were placed at a distance of 20 to 25 mm (center to center) from the amoxicillin-clavulanic acid disc on the same plate. After incubation of 18 to 24 h at 37°C zones of inhibition around the 3rd generation cephalosporin discs were observed. The microorganism was labeled as ESBL positive if the zone of inhibition around one or more cephalosporin discs was extended on the side nearest to the amoxicillin/clavulanic acid. The double-disk synergy test was used as the phenotypic confirmatory test where the test bacteria were grown on Mueller-Hinton agar and discs of cefotaxime and ceftazidime separately and each of these in combination with clavulanic acid were placed on the surface of plate with inoculated bacteria.

The microorganism was considered as ESBL positive isolate if

**Table 1.** *In vitro* resistance to antimicrobials of ESBL-positive and ESBL-negative *K. pneumoniae* strains isolated from blood in 2009.

| Antibiotic                  | ESBL + (No = 16) |               | ESBL - (No = 14) |               |
|-----------------------------|------------------|---------------|------------------|---------------|
|                             | Sensitive (%)    | Resistant (%) | Sensitive (%)    | Resistant (%) |
| Ampicillin                  | 0 (0)            | 16 (100)      | 0 (0)            | 14 (100)      |
| Cefazolin                   | 0 (0)            | 16 (100)      | 7 (50)           | 7 (50)        |
| Ceftriaxone                 | 0 (0)            | 16 (100)      | 11 (78.6)        | 3 (21.4)      |
| Ceftazidime                 | 0 (0)            | 16 (100)      | 11 (78.6)        | 3 (21.4)      |
| Piperacillin/tazobactam     | 9 (56.3)         | 7 (43.7)      | 13 (92.9)        | 1 (7.1)       |
| Amoxicillin/clavulanic acid | 4 (25)           | 12 (75)       | 10 (71.4)        | 4 (28.6)      |
| Imipenem                    | 16 (100)         | 0 (0)         | 14 (100)         | 0 (0)         |
| Meropenem                   | 16 (100)         | 0 (0)         | 14 (100)         | 0 (0)         |
| Ertapenem                   | 16 (100)         | 0 (0)         | 14 (100)         | 0 (0)         |
| Gentamicin                  | 4 (25)           | 12 (75)       | 14 (100)         | 0 (0)         |
| Amikacin                    | 9 (56.3)         | 7 (43.7)      | 14 (100)         | 0 (0)         |
| Cotrimoxazole               | 1 (6.3)          | 15 (93.7)     | (78.6)           | 3 (21.4)      |
| Ciprofloxacin               | 3 (18.7)         | 13 (81.3)     | (78.6)           | 3 (21.4)      |

there was the difference of  $\geq 5$  mm between the zone of inhibition of a single antibiotic and in disc with combination of antibiotic and clavulanic acid (CLSI, 2009, 2010).

#### Statistical analysis

Laboratory data were entered into a database using SPSS (statistical package for the social sciences) for Windows. The  $\chi^2$  test was used to compare variables. All differences in which the probability of the null hypothesis was  $p < 0.05$  were considered significant.

## RESULTS

*K. pneumoniae* was the 3rd leading isolated microorganism and the 2nd one among Gram-negative isolates out of the total 883. The frequency of isolation of *K. pneumoniae* was 7.5% (30 of 398 isolates) in 2009 and 9.7% (47 of 485 isolates) in 2010. There was a high frequency of ESBL-producing *K. pneumoniae* in both years: 53.3% (16 out of 30) and 68.1% (32 out of 47) in 2009 and 2010 respectively. Despite the increase of incidence, the difference was not statistically significant. Resistance to piperacillin/tazobactam increased from 43.7 to 75% from 2009 to 2010, while for amoxicillin/clavulanic acid decreased from 75 to 71.9% in the same period. Among ESBL-producing strains, a total of 43 isolates (89.6%) were multidrug resistant (MDR). The most common MDR pattern was resistance to beta-lactams, aminoglycosides, cotrimoxazole and fluoroquinolones. Resistance to all antibiotics tested except carbapenems was higher in the ESBL-producing strains compared to the non-ESBL-producing bacteria. The most effective antibiotics for ESBL-producing strains were carbapenems which included imipenem, meropenem and ertapenem. Carbapenems had 100%

activity in both years of investigation. Resistance to antimicrobial drugs during two years period is given in Tables 1 and 2. ESBL-producing *K. pneumoniae* were most commonly isolated in intensive care unit of the clinical center. The finding of ESBL-producing isolates in each ward of the Centre is shown in Table 3. The age of patients included in this study during 2009 to 2010 ranged from 20 to above 60 years. For the purposes of the study, patients were divided in different age groups: group I - patients from 20 to 39 years ( $n = 19$ , 24.7%), group II - patients from 40 to 59 years of age ( $n = 25$ , 32.5%) and group III patients above 60 years of age ( $n = 33$ , 42.8%). There was a significant difference between the first and the third age group of patients with bacteremia due to ESBL producing and non-ESBL producing strains ( $p$  value  $< 0.05$ ).

A total of 66.2% of the patients were males. According to the gender, a higher proportion of patients with ESBL-producing strains were found in the group of males ( $p$  value  $< 0.05$ ) (Table 4).

## DISCUSSION

The frequency of ESBL-producing isolates varies according to countries, region or even hospitals and is rapidly changing over time (Kader and Kumar, 2005). During the past decade, ESBL-producing *K. pneumoniae* has emerged as serious pathogen in hospitals worldwide. Recent studies revealed that patients with septicemia caused by ESBL producing organisms had significantly higher fatality rate than those with non-ESBL isolates (Mahrgan and Rahabar, 2008). In recent years, incidence of ESBL-producing *K. pneumoniae* is increased in many of the European countries such as Bulgaria, Greece, Croatia, Czech Republic, Italy and Hungary

**Table 2.** *In vitro* resistance to antimicrobials of ESBL-positive and ESBL-negative *K. pneumoniae* strains isolated from blood in 2010.

| Antibiotic                  | ESBL + (No = 32) |               | ESBL - (No = 15) |               |
|-----------------------------|------------------|---------------|------------------|---------------|
|                             | Sensitive (%)    | Resistant (%) | Sensitive (%)    | Resistant (%) |
| Ampicillin                  | 0 (0)            | 32 (100)      | 0 (0)            | 15 (100)      |
| Cefazolin                   | 0 (0)            | 32 (100)      | 11 (73.3)        | 4 (26.7)      |
| Ceftriaxone                 | 0 (0)            | 32 (100)      | 11 (73.3)        | 4 (26.7)      |
| Ceftazidime                 | 0 (0)            | 32 (100)      | 11 (73.3)        | 4 (26.7)      |
| Piperacillin/tazobactam     | 8 (25)           | 24 (75)       | 11 (73.3)        | 4 (26.7)      |
| Amoxicillin/clavulanic acid | 9 (28.1)         | 23 (71.9)     | 11 (73.3)        | 4 (26.7)      |
| Imipenem                    | 32 (100)         | 0 (0)         | 15 (100)         | 0 (0)         |
| Meropenem                   | 32 (100)         | 0 (0)         | 15 (100)         | 0 (0)         |
| Ertapenem                   | 32 (100)         | 0 (0)         | 15 (100)         | 0 (0)         |
| Gentamicin                  | 14 (43.7)        | 18 (56.3)     | 12 (80)          | 3 (20)        |
| Amikacin                    | 16 (50)          | 16 (50)       | 12 (80)          | 3 (20)        |
| Cotrimoxazole               | 4 (25)           | 28 (87.5)     | 10 (66.7)        | 5 (33.3)      |
| Ciprofloxacin               | 2 (6.3)          | 30 (93.7)     | 11 (73.3)        | 4 (26.7)      |

**Table 3.** ESBL-positive and ESBL-negative *K. pneumoniae* isolates based on ward of admission.

| Ward                      | 2009      |           | 2010      |           | Total     |          |
|---------------------------|-----------|-----------|-----------|-----------|-----------|----------|
|                           | ESBL+(%)  | ESBL-(%)  | ESBL+(%)  | ESBL-(%)  | ESBL+(%)  | ESBL-(%) |
| Internal                  | 6 (7.8)   | 4 (5.2)   | 6 (7.8)   | 4 (5.2)   | 12 (15.6) | 8 (10.4) |
| Surgery                   | 4 (5.2)   | 1 (1.3)   | 6 (7.8)   | 2 (2.6)   | 10 (13)   | 3 (3.9)  |
| Intensive care unit (ICU) | 5 (6.5)   | 2 (2.6)   | 14 (18.2) | 5 (6.5)   | 19 (24.6) | 7 (9.1)  |
| Obstetrics and gynecology | 0 (0)     | 1 (1.3)   | 1 (1.3)   | 0 (0)     | 1 (1.3)   | 1 (1.3)  |
| Other                     | 1 (1.3)   | 6 (7.8)   | 5 (6.5)   | 4 (5.2)   | 6 (7.8)   | 10 (13)  |
| Total                     | 16 (20.8) | 14 (18.2) | 32 (41.6) | 15 (19.5) | 77 (100)  |          |

**Table 4.** Demographic characteristics of patients according to ESBL producing *Klebsiella pneumoniae* bloodstream infection during 2009 to 2010.

| Variables        | ESBL + (%) | ESBL - (%) | Total (%) |
|------------------|------------|------------|-----------|
| <b>Sex</b>       |            |            |           |
| Male             | 32 (66.7)  | 19 (65.5)  | 51 (66.2) |
| Female           | 16 (33.3)  | 10 (34.5)  | 26 (33.8) |
| <b>Age group</b> |            |            |           |
| 20-39            | 13 (27.1)  | 6 (20.7)   | 19 (24.7) |
| 40-59            | 14 (29.2)  | 11 (37.9)  | 25 (32.5) |
| > 60             | 21 (43.7)  | 12 (41.4)  | 33 (42.8) |

(Eurosurveillance, 2010). In this study, *K. pneumoniae* was found to be the third most common etiological agent of bloodstream infections. Similar data are found by Al-Hasan et al. (2010a, b). The most prevalent ESBL-producing *K. pneumoniae* were isolated from patients in ICU ward of the Hospital which is in accordance with Paterson et al. (2003) and Ferrandez et al. (2011). In this

study, the incidence of ESBL-producing *K. pneumoniae* isolated from blood was 53.3% in 2009 and 68.1% in 2010. Despite the increase of incidence, this difference was not statistically significant ( $p$  value > 0.05). ESBL prevalence varies in different countries. In some European countries, frequency of ESBL-producing *K. pneumoniae* is below 5% (Switzerland, Finland, Iceland,

Malta, Norway and Sweden) (Eurosurveillance, 2010). The ESBLs prevalence rate in this study was much higher than those reported in Iran (6.25%, Ramazanzadeh), Korea (15.9%, Kang), Thailand (23.7%, Musikatavorn), and in European countries [Slovenia (26%), Hungary (35%), Poland (37%), Italy (38%), Bosnia and Herzegovina (44%), Czech Republic (48%)] (Kang et al., 2004; Ramazanzadeh, 2010; Musikatavorn et al., 2011; Eurosurveillance, 2010).

Similar findings have been reported from some neighboring countries such as Bulgaria (73%), Greece (66%), Croatia (54%) (Eurosurveillance, 2009) and also by Abhilash who found that 72.4% isolates of *K. pneumoniae* were ESBL-producing in India (Abhilash et al., 2010). In a Turkish study by Serefhanoglu nearly 61% of blood culture isolates were ESBL-producing (Serefhanoglu et al., 2009) and the rate of 51.8% of ESBL-producing *K. pneumoniae* in bloodstream infection was found by Marra in the Brazilian hospital (Marra et al., 2006). Resistance to other antimicrobial drugs among ESBL-producing *K. pneumoniae* was commonly found. Resistance to gentamicin was higher than amikacin. Resistance to cotrimoxazole and ciprofloxacin was higher than 80%. In this study, statistically significant increase of the resistance to piperacillin/tazobactam in 2010, compared to the results in 2009 was found ( $p$  value < 0.05). The increase of the resistance to amikacin and ciprofloxacin in 2010 was not significant ( $p$  value > 0.05). The susceptibility to non-beta-lactam agents in the ESBL-positive group was significantly lower than in ESBL-negatives. Resistance to carbapenem was not found in this study. KPC-positive bacteria were present in 1.3% of bacteremia episodes in a study by Marschall (Marschall et al., 2009). Presence of carbapenem resistant *K. pneumoniae* in bloodstream infection also confirms Mouloudi from Greece (Mouloudi et al., 2010). Carbapenem resistance is still rare in most countries. Seven European countries reported from 1 to 5% resistant strains (Bosnia and Herzegovina, Italy, Latvia, Norway, Portugal, Turkey and United Kingdom), but in three countries carbapenem resistance is considerably higher: Cyprus (10%), Israel (19%) and Greece (37%) (Eurosurveillance, 2010).

Some European authors reported emerging infections with NDM-1 producing strains (Eurosurveillance, 2010). Carbapenems are widely used for the treatment of infections caused by multidrug resistant gram-negative bacteria that produce extended-spectrum beta-lactamases. Several investigators have concluded that initial treatment of bloodstream infections caused by ESBL-producing strains with non-carbapenem agents may be associated with higher mortality than treatment with a carbapenem agent (Ambretti et al., 2010). In conclusion, our study shows a very high prevalence of ESBL-producing *K. pneumoniae* among hospitalized patients with bloodstream infections. Very high rates of resistance to all tested classes of antimicrobials except carbapenems we noted. These data suggest that amikacin

should be considered as synergistic antibiotic for the treatment of these infections, together with other antimicrobial drug. The study also highlights the need for the continual monitoring of antimicrobial susceptibility patterns of important bacterial pathogens so that rational antibiotic policies could be formulated. Further drug resistance surveillance is necessary in our hospitals as well as molecular characterization of ESBL isolates.

## REFERENCES

- Abbott SL (2003). *Klebsiella*, *Enterobacter*, *Citrobacter*, *Serratia*, *Plesomonas* and Other Enterobacteriaceae in Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC Manual of Clinical Microbiology, 8<sup>th</sup> ed. Washington; ASM Press: 684-696.
- Abhilash KPP, Veeraraghavan B, Abraham OC (2010). Epidemiology and Outcome of Bacteremia Caused by Extended Spectrum Beta-Lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella* Spp. in a Tertiary Care Teaching Hospital in South India. JAPI., 58 (Suppl): 13-17.
- Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM (2010a). Epidemiology and Outcome of *Klebsiella* Species Bloodstream Infection: A Population-Based Study. Mayo. Clin. Proc., 85(2):139-144.
- Al-Hasan MN, Eckel-Passow JE, Baddour LM (2010b). Recurrent Gram-Negative Bloodstream Infection: A 10-Year Population-Based Cohort Study. J. Infect., 61(1):28-33.
- Ambretti S, Gaibani P, Caroli F, Marigliotta L, Sambri V (2010). A Carbapenem-Resistant *Klebsiella pneumoniae* Isolate Harboring KPC-1 from Italy. New Microbiologica., 33:281-282.
- Behrooz A, Rahbar M, Yousefi JV (2010). Frequency of extended spectrum beta-lactamase (ESBLs) producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from urine in an Iranian 1000-bed tertiary care hospital. Afr. J. Microbiol. Res., 4(9):881-884.
- CLSI (2009). Performance Standards for Antimicrobial Susceptibility Testing. Nineteenth informational supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute.
- CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing. Twentieth informational supplement. CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
- Dallenne C, Da Costa A, Decre D, Favier C, Arlet G (2010). Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in *Enterobacteriaceae*. J. Antimicrob. Chemother., 65(3): 490-495.
- Eurosurveillance (2009). European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2010:47-56.
- Ferrandez O, Grau S, Saballs P, Luque S, Terradas R, Salas E (2011). Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms. Rev. Clin. Esp., 211(3):119-126.
- Gagliotti C, Sarti M, Benini F, Cipolloni AP, Testa G, Venturelli C, Moro ML (2008). Laboratory Detection of Extended-Spectrum Beta-Lactamase by an Automated System. New Microbiologica., 31:561-564.
- Giakkoupi P, Pappa O, Polemis M, Vatapoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouveleki LS (2009). Emerging *Klebsiella pneumoniae* isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob. Agents Chemother., 53(9): 4048-4050.
- Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, Vatapoulos A, Gniadkowski M, Toth A, Pfeifer Y, Jarlier V, Carmeli Y, CNSE Working Group (2011). Carbapenem-non-susceptible *Enterobacteriaceae* in Europe: conclusion from a meeting of national experts. Eurosurveillance., 21-33.
- Kader AA, Kumar A (2005). Prevalence and Antimicrobial Susceptibility of Extended-Spectrum Beta-Lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in a General Hospital. Ann. Aud. Med., 25(3):239-242.

- Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004). Bloodstream infections due to extended-spectrum beta-lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. *Antimicrob. Agents Chemother.*, 48(12):4574-4581.
- Marra AR, Wey SB, Castelo A, Gales AC, Cai RGR, Filho JRC, Edmond MB, Pereira CA (2006). Nosocomial Bloodstream Infections caused by *Klebsiella pneumoniae*: Impact of Extended-spectrum  $\beta$ -lactamase (ESBL) production on clinical outcome in a Hospital with High ESBL Prevalence. *BMC Infect. Dis.*, 6:24.
- Marschall J, Teibbetts RJ, Dunne JrWM, Frey JG, Fraser VJ, Warren DK (2009). Presence of the KPC Carbapenemase Gene in *Enterobacteriaceae* Causing Bacteremia and Its Correlation with In Vitro Carbapenem Susceptibility. *J. Clin. Microbiol.*, 47(1):239-241.
- Mehrgan H, Rahbar M (2008). Prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* in a tertiary care hospital in Tehran, Iran. *Int. J. Antimicrob. Agents* 31(2): 147-151.
- Musikataporn K, Chumpengpan C, Sujinpram C (2011). Risk factors of extended-spectrum beta-lactamase producing *Enterobacteriaceae* bacteremia in Thai emergency department: a retrospective case-control study. *Asian Biomed.*, 5(1):129-138.
- Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. (2003). Antibiotic Therapy for *Klebsiella pneumoniae* Bacteremia: Implication of Production of Extended-Spectrum  $\beta$ -Lactamases. *Clin. Infect. Dis.*, 39:31-37.
- Paterson DL, Bonomo RA (2005). Extended-Spectrum Beta-Lactamases: A Clinical Update. *Clin. Microbiol. Rev.*, 18 (4): 657-686.
- Ramazanadeh R (2010). Prevalence and characterization of extended-spectrum beta-lactamase production in clinical isolates of *Klebsiella* spp. *Afr. J. Microbiol. Res.*, 4(13): 1359-1362.
- Samuelsen O, Naseer U, Tofteland S, Skutlaberg DH, Onken A, Hjetland R, Sundsfjord A, Giske CG (2009). Emergence of clonally related *Klebsiella pneumoniae* isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. *J. Antimicrob. Chemother.*, 63(4): 654-658.
- Serephanoglu K, Turan H, Timurkaynak FE, Arslan H (2009). Bloodstream Infections Caused by ESBL-producing *E.coli* and *K. pneumoniae*: Risk Factors for Multidrug-resistance. *Braz. J. Infec. Dis.*, 13(6): 403-407.
- Shayanfar N, Razaee M, Ahmadi M, Ehanipour F (2010). Evaluation of Extended Spectrum Betalactamase (ESBL) Positive Strains of *Klebsiella pneumoniae* and *Escherichia coli* in Bacterial Cultures. *Iranian J. Pathol.*, 5(1): 34-39.
- Woodford N, Tierno jr PM, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Korublum J, Livermore DM (2004). Outbreak of *Klebsiella pneumoniae* producing new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. *Antimicrob. Agents Chemother.*, 48(12): 4793-4799.